No products
View larger AOB31775
CAS No: 57754-86-6
1000 Items
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $11.05 | Total: $55.25 |
| 1 | 10 | $9.36 | Total: $93.60 |
| 1 | 25 | $7.93 | Total: $198.25 |
| 1 | 50 | $6.76 | Total: $338.00 |
| 1 | 100 | $5.85 | Total: $585.00 |
| Molecular Formula | C17H21NO2.HCl |
| Molecular Weight | 307.82 |
| CAS Numbers | 57754-86-6 |
| Storage Condition | +4C |
| Solubility | 100 mM in water |
| Purity | 99% (HPLC) |
| IUPAC/Chemical Name | γ-(2-methoxyphenoxy)-N-methyl-benzenepropanamine, monohydrochloride |
| InChl Key | LCEURBZEQJZUPV-UHFFFAOYSA-N |
| InChl Code | InChI=1S/C17H21NO2.ClH/c1-18-13-12-15(14-8-4-3-5-9-14)20-17-11-7-6-10-16(17)19-2;/h3-11,15,18H,12-13H2,1-2H3;1H |
| SMILES Code | CNCCC(C1=CC=CC=C1)OC2=C(OC)C=CC=C2.Cl |
| References | 1) Torres, G.E., Gainetdinov, R.R., and Caron, M.G. Plasma membrane monoamine transporters: Structure, regulation and function. Nat. Rev. Neurosci. 4(1), 13-25 (2003). 2) Tyler, T.D., and Tessel, R.E. Amphetamine’s locomotor-stimulant and noreprinephrine-releasing effects: Evidence for selective antagonism by nisoxetine. Psychopharmacology (Berl) 64(3), 291-296 (1979). |
Potent and selective inhibitor of the norepinephrine transporter
Nisoxetine hydrochloride is a selective norepinephrine reuptake inhibitor (NRI). It is primarily used in research rather than as an approved therapeutic drug.
1. Selective inhibition of norepinephrine reuptake
Nisoxetine blocks the norepinephrine transporter (NET) on presynaptic neurons.
This increases norepinephrine levels in the synaptic cleft.
Enhances noradrenergic signaling in the brain and peripheral nervous system.
2. High selectivity
It has minimal effect on serotonin (SERT) and dopamine (DAT) reuptake systems compared to its strong action on NET.
Because of this selectivity, it is often used in experiments to differentiate NET function from other monoamine systems.
3. Research applications
Nisoxetine is commonly used to:
Study NET density and distribution via radiolabeled derivatives.
Investigate noradrenergic involvement in mood regulation, attention, pain perception, and autonomic function.
Characterize pharmacodynamics of antidepressants that target norepinephrine.
4. Not approved for clinical use
Despite being developed as an antidepressant candidate, it was never marketed.
Its role is largely preclinical and experimental.